Fixed-dose combinations of bronchodilators in the treatment of patients with COPD: problem of choice

Abstract

Chronic Obstructive Pulmonary Disease (COPD) is a disease characterized by air flow limitation that progresses over time and is not fully reversible, which, along with the severity of clinical symptoms and the frequency of relapses, is one of its key characteristics [1, 2]. The main “tool” in achieving therapeutic goals in accordance with current guidelines GOLD [1], GesEPOC [3], NICE [4], PPO [5], etc. - are bronchodilators. Fixed-dose combinations of long acting beta-2 agonists/long acting anticholinergic agents provide optimal bronchodilation and play a primary role in preventing exacerbations of COPD.

Keywords

• chronic obstructive pulmonary disease
• fixed-dose combinations of laba/laac
• vilantherol/umeclidinium